Mark H. Mirochnick, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Pediatrics
Neonatology

MD, University of Vermont College of Medicine
BSc, Dickinson College



Mark Mirochnick, MD is Professor of Pediatrics and a member of the Division of Neonatology at Chobanian and Avedisian School of Medicine/Boston Medical Center. His main research activities involve investigating the pharmacology of HIV and TB drugs in newborns, infants, children and pregnant women. He has served as protocol chair, investigator and/or protocol pharmacologist on many international protocol teams in this area. He currently serves as co-chair of the US Perinatal HIV Guidelines Committee and is a member of the US Pediatric HIV Guidelines Committee and the WHO Pediatric Antiretroviral Working Group.

Section Director
Boston University Chobanian & Avedisian School of Medicine
Pediatrics
Neonatology



A 48 Week, Phase II, Open-Label, Multi-Cohort, Multicenter Study to Evaluate the Safety , Tolerability, Pharmacokinetics, and Antiviral Activity of GW433908/Ritonavir QD when Administered to HIV-1 Infected, Antiretrovitral Naive and Experienced, Pediatric
07/01/2002 - 06/30/2006 (PI)
GlaxoSmithKline, Inc.

Open-Label Multicenter Multiple Dose Phase III Study of the Population Pharmacokinetics of IV Synecid 7.5 mg/kg q8h in &5 Pediatric Patients
11/01/2001 - 10/31/2003 (PI)
Aventis Pharmaceuticals Inc

Investigation of CD11b Expression in Neonates Using New Laser Scanning Cytometer Technology
10/19/1999 - 09/30/2000 (PI)
CompuCyte Corporation


IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
07/01/2022 - 06/30/2025 (PI)
Johns Hopkins University ViiV Healthcare

IMPAACT Leadership Group - 2032 Protocol Chair (remdescivir)
07/01/2023 - 11/30/2024 (PI)
Johns Hopkins University National Institute o

LDR 01: LOC-IMPAACT Leadership Group: Mirochnick
01/01/2014 - 11/30/2024 (PI)
Johns Hopkins University National Institute o
5UM1AI068632-18

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
12/01/2021 - 06/30/2023 (PI)
Johns Hopkins University Gilead Sciences

?P1026S - IMPAACT 1026S Pharmacokinetic Properties of ARVs during Pregnancy and Postpartum
07/01/2021 - 12/31/2022 (PI)
Johns Hopkins University National Institute o
5UM1AI068632-17

Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
06/01/2020 - 11/30/2022 (PI)
Johns Hopkins University National Institute o
3UM1AI068632-14S2

Enhanced maternal and fetal PBPK models to predict drug exposures of novel oral and long-acting antivirals during pregnancy
08/09/2020 - 07/31/2022 (PI)
The Regents of the University of Calif., U.C. San Diego National Institute o
5R21HD102856-02

LDR09 - P1026s: Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy...
07/01/2019 - 06/30/2021 (PI)
Johns Hopkins University Gilead Sciences

IMPAACT 2007 - Phase I Safety and Pharmacokeneticks of Marviorc in HIV 1 Exposed Infants at Risk …
07/01/2016 - 12/31/2020 (PI)
Johns Hopkins University PHIVCO UK II Ltd

Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials
12/01/2012 - 11/30/2016 (PI)
Univ of California, San Francisco NIH-NIAID

Showing 10 of 21 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs
2008 Safety Pharmacokinetics &Efficacy of Artemether &Lumefantrine in Pregnant Women 1R34AI076610-01
2007 PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN 2M01RR000533-39-8160 503
2007 ANTIRETROVIRAL DRUGS DURING PREGNANCY, SUBSTUDY OF PACTG P1025 2M01RR000533-39-8139 503
2007 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 2M01RR000533-39-8144 503
2006 ANTIRETROVIRAL DRUGS DURING PREGNANCY, HIV INFECTED WOMEN (SUB OF PACTG P1025) 5M01RR000533-38-5584 503
2006 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-38-5591 503
2006 Antiretroviral Pharmacology/Lactating Mother/Infants 5R21HD051470-02 1
2005 Antiretroviral Pharmacology/Lactating Mother/Infants 1R21HD051470-01 1
2005 PERINATAL CORE PROTOCOL IN HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-37-444 503
2005 ANTIRETROVIRAL DRUGS DURING PREGNANCY IN HIV POSITIVE FEMALES 5M01RR000533-37-5424 503
Showing 10 of 22 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Bekker A, Yang J, Wang J, Cotton MF, Cababasay M, Wiesner L, Moye J, Browning R, Nakwa FL, Rabie H, Violari A, Mirochnick M, Cressey TR, Capparelli EV. Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360. PMID: 38190642; PMCID: PMC10939833; DOI: 10.1097/INF.0000000000004243;
     
  2. Persaud D, Bryson Y, Nelson BS, Tierney C, Cotton MF, Coletti A, Jao J, Spector SA, Mirochnick M, Capparelli EV, Costello D, Szewczyk J, Nicodimus N, Stranix-Chibanda L, Kekitiinwa AR, Korutaro V, Reding C, Carrington MN, Majji S, Yin DE, Jean-Philippe P, Chadwick EG. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024 Jan; 11(1):e20-e30. PMID: 38061376
     
  3. Momper JD, Nikanjam M, Best BM, Mirochnick M, Capparelli EV, Cressey TR. Brief Report: Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum. J Acquir Immune Defic Syndr. 2023 Dec 01; 94(4):332-336. PMID: 37884053; PMCID: PMC10686188; DOI: 10.1097/QAI.0000000000003281;
     
  4. Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, Eke AC, Cressey TR, Shapiro DE, Bacon K, Knowles K, George K, Browning R, Chakhtoura N, Rungruengthanakit K, Wiesner L, Capparelli EV, Stek AM, Mirochnick M, Best BM. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023 Nov 15; 67(11):e0073723. PMID: 37882552; PMCID: PMC10648924; DOI: 10.1128/aac.00737-23;
     
  5. Brooks KM, Scarsi KK, Mirochnick M. Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy. Obstet Gynecol Clin North Am. 2023 Mar; 50(1):205-218. PMID: 36822704
     
  6. Eke AC, Mirochnick M, Lockman S. Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV. N Engl J Med. 2023 Jan 26; 388(4):344-356. PMID: 36720135; PMCID: PMC10400304; DOI: 10.1056/NEJMra2212877;
     
  7. Liu XI, Dallmann A, Brooks K, Best BM, Clarke DF, Mirochnick M, van den Anker JN, Capparelli EV, Momper JD. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2023 Feb; 12(2):148-153.View Related Profiles. PMID: 36479969; PMCID: PMC9877749; DOI: 10.1002/psp4.12900;
     
  8. Coutinho CM, Warshaw MG, Duarte G, Stek A, Violari A, Hofer CB, Deville JG, Ngocho JS, Pilotto JH, Correa MD, Shapiro DE, Fuller TL, Chakhtoura N, Mirochnick M, João EC. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081. J Acquir Immune Defic Syndr. 2022 Dec 01; 91(4):403-409. PMID: 36049477; PMCID: PMC9613542; DOI: 10.1097/QAI.0000000000003081;
     
  9. Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents. Clin Infect Dis. 2022 Nov 21; 75(Suppl 4):S562-S570. PMID: 36410381; PMCID: PMC10200315; DOI: 10.1093/cid/ciac754;
     
  10. Béranger A, Bekker A, Solans BP, Cotton MF, Mirochnick M, Violari A, Wang J, Cababasay M, Wiesner L, Browning R, Moye J, Capparelli EV, Savic RM. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. Clin Infect Dis. 2022 Sep 29; 75(6):1037-1045. PMID: 35134861; PMCID: PMC9522418; DOI: 10.1093/cid/ciac001;
     
Showing 10 of 159 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 159 publications over 36 distinct years, with a maximum of 14 publications in 2020

YearPublications
19863
19881
19901
19911
19933
19943
19951
19962
19971
19983
19997
20004
20013
20023
20033
20041
20054
20063
20072
20086
20093
20103
20119
20125
20134
20147
20155
20162
20174
201810
201911
202014
202112
20229
20235
20241
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Neonatology
Contact for Mentoring:

771 Albany St
Boston MA 02118
Google Map


Mirochnick's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department